{"id":"W2057332288","doi":"10.1185/03007995.2013.837817","title":"Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes","year":2013,"lang":"en","type":"review","venue":"Current Medical Research and Opinion","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Canadian Diabetes Association","keywords":"Medicine; Exenatide; Liraglutide; Metformin; Type 2 diabetes; Incretin; Hypoglycemia; Glucagon-like peptide 1 receptor; Diabetes mellitus; Internal medicine; Glycemic; Clinical trial; Pharmacology; Endocrinology; Agonist; Receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001446593,0.0003815054,0.001650082,0.0007680125,0.00006116565,0.00008198334,0.0002866395,0.000385557,0.0006634984],"category_scores_gemma":[0.002097558,0.0002614882,0.0002144188,0.0008276416,0.0004731021,0.0001540223,0.0004738585,0.001215995,0.0003718637],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001906566,"about_ca_system_score_gemma":0.0006764113,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007269972,"about_ca_topic_score_gemma":0.0000050581,"domain_scores_codex":[0.9955902,0.0004281719,0.0007895688,0.0006216351,0.001725065,0.0008453545],"domain_scores_gemma":[0.9971874,0.001032551,0.000163753,0.0004975445,0.0002827237,0.0008360584],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000283736,0.0005664055,0.0009095655,0.02334165,0.0001610271,0.000007565419,0.00003138043,3.482249e-9,5.390556e-7,0.0001658049,0.04982826,0.9249594],"study_design_scores_gemma":[0.0008209501,0.001027911,0.0005439605,0.04770738,0.00009706641,9.259667e-7,0.000007793792,0.00001195112,0.000002085621,0.00003826012,0.9495579,0.0001838195],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003349635,0.9925925,0.000001541233,0.000200638,0.001390891,0.002176951,0.00002411795,0.00002572987,0.000238048],"genre_scores_gemma":[0.00008339648,0.9968753,0.00007032239,0.00001715322,0.0004081392,0.0003235328,0.0009648315,0.00004719496,0.001210167],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9247756,"threshold_uncertainty_score":0.9999837,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2269259120738071,"score_gpt":0.4576717572343769,"score_spread":0.2307458451605697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}